Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HBM 9022

Drug Profile

HBM 9022

Alternative Names: 47D11 - Harbor Biomed/Erasmus University Medical Center/University of Utrecht; Anti-coronavirus antibody - Harbor Biomed/Erasmus University Medical Center/University of Utrecht; HBM9022

Latest Information Update: 12 May 2020

At a glance

  • Originator Erasmus MC; Harbour BioMed; Utrecht University
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 12 May 2020 Preclinical trials in COVID-2019 infections (Prevention) in Netherlands (Parenteral), prior to May 2020 (Harbour BioMed pipeline, May 2020)
  • 12 May 2020 Preclinical trials in COVID-2019 infections in Netherlands (Parenteral), prior to May 2020 (Harbour BioMed pipeline, May 2020)
  • 31 Mar 2020 Anti-coronavirus antibodies is available for licensing as of 23 Mar 2020. http://www.harbourbiomed.com/en/partner.html

Development Overview

Introduction

HBM 9022 is a monoclonal antibody, neutralising the spike proteins of SARS-CoV-2, being jointly developed by Harbor Biomed, Erasmus University Medical Center and University of Utrecht, for the treatment and prevention of SARS-CoV-2 coronavirus (COVID-2019) infections. The first human monoclonal antibody (47D11) can block the attachment of the SARS-CoV-2 coronavirus. Preclinical development is underway in the Netherlands.

Harbor Biomed uses patented transgenic mouse platforms (Harbour Mice®) for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies (Harbor Biomed website, March 2020).

Harbor Biomed is looking for partnership opportunities for further development of antibodies (Harbor Biomed website, March 2020).

Key Development Milestones

In March 2020, the first human monoclonal antibody (47D11) was identified that binds to cells expressing the full-length spike proteins of SARS-CoV and SARS-CoV-2 [1] [2] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antivirals, Monoclonal antibodies
  • Target Coronavirus spike glycoprotein
  • Mechanism of Action Immunomodulators
  • WHO ATC code

    J05 (Antivirals for Systemic Use)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical Netherlands Parenteral / unspecified Erasmus MC, Utrecht University, Harbour BioMed 12 May 2020
COVID 2019 infections - - Preclinical Netherlands Parenteral / unspecified Erasmus MC, Utrecht University, Harbour BioMed 12 May 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Harbour BioMed Originator China
Erasmus MC Originator Netherlands
Utrecht University Originator Netherlands
Utrecht University Owner Netherlands
Erasmus MC Owner Netherlands
Harbour BioMed Owner China

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Harbour BioMed - Unspecified - 23 Mar 2020

Development History

Event Date Update Type Comment
12 May 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections (Prevention) in Netherlands (Parenteral), prior to May 2020 (Harbour BioMed pipeline, May 2020) Updated 12 May 2020
12 May 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections in Netherlands (Parenteral), prior to May 2020 (Harbour BioMed pipeline, May 2020) Updated 12 May 2020
31 Mar 2020 Licensing Status Anti-coronavirus antibodies is available for licensing as of 23 Mar 2020. http://www.harbourbiomed.com/en/partner.html Updated 06 Apr 2020
23 Mar 2020 Phase Change Early research in COVID-2019 infections (Prevention) in Netherlands (Parenteral) before March 2020 [1] Updated 06 Apr 2020
23 Mar 2020 Phase Change Early research in COVID-2019 infections in Netherlands (Parenteral) before March 2019 [1] Updated 06 Apr 2020

References

  1. Human antibody to new coronavirus.

    Media Release
  2. COVID-19-Utrecht University. Internet-Doc 2020;.

    Available from: URL: https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf
Back to top